Quick Dispatch:
Your tirzepatide surmount 5 SURMOUNT-5: Comparing Tirzepatide (TZP) to Semaglutide (SMG) in the Treatment of Obesity . Super Summary: . 💡TZP is superior to SMG in achieving weight loss. . 💡A higher proportion of patients on orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount 5 SURMOUNT-5: Comparing Tirzepatide (TZP) to Semaglutide (SMG) in the Treatment of Obesity . Super Summary: . 💡TZP is superior to SMG in achieving weight loss. . 💡A higher proportion of patients on ships.
Need Help?
Questions about tirzepatide surmount 5 SURMOUNT-5: Comparing Tirzepatide (TZP) to Semaglutide (SMG) in the Treatment of Obesity . Super Summary: . 💡TZP is superior to SMG in achieving weight loss. . 💡A higher proportion of patients on, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount 5 SURMOUNT-5: Comparing Tirzepatide (TZP) to Semaglutide (SMG) in the Treatment of Obesity . Super Summary: . 💡TZP is superior to SMG in achieving weight loss. . 💡A higher proportion of patients on in your area.
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary:
21.02
ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide's lead in CVD risk reduction
24.23
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
25.11
Zepbound Shows Superior Weight Loss Compared to Wegovy in SURMOUNT-5 Trial
29.04
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
23.07
Presented at #ECO2025: In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results:
19.99
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
22.37
